Amyloidosis and TAVR: Does this Disease Have an Impact?

Amyloidosis is a systemic disease that affects different organs and impairs their function.

Amiloidosis y TAVI: ¿tiene impacto esta enfermedad?

Recent studies with magnetic resonance imaging (MRI) have shown that between 13% and 16% of patients who undergo transcatheter aortic valve replacement (TAVR) have amyloidosis. 

A review of four studies showed that mortality at 20 months was twice as high when amyloidosis was present after device implantation. However, other more recent studies show no difference in mortality.

Researchers analyzed the US NRD (Nationwide Readmissions Database) from January 2016 to December 2019 and included 244,967 hospitalizations for TAVR. Among these cases, 273 patients had amyloidosis (0.11%).

Mean age was 79 years and most subjects were female. There was a greater presence of atrial fibrillation and impaired renal function. However, these patients also exhibited lower levels of hypertension, diabetes, and MRS.

There were no differences in in-hospital mortality or 30-day readmissions (1.8% vs. 1.5%, p = 0.622; and 12.9% vs. 12.5%, p = 0.858; respectively). The rate of acute ischemic stroke was higher in patients with amyloidosis (6.2% vs. 1.8%, p < 0.001), and so was the rate of acute ischemic and hemorrhagic stroke (7.2% vs. 1.8%, p < 0.001).

Read also: TriClip: Tricuspid Regurgitation Dedicated Device.

A propensity score was estimated by logistic regression and results showed that the group with amyloidosis was associated with a higher risk of acute ischemic stroke (odds ratio [OR] 3.08; 95% confidence interval [CI]: 1.41-6.71; p = 0.005), but there were no differences in mortality (OR: 0.79; 95% CI: 0.28-2.27, p = 0.666) and 30-day readmissions (hazard ratio: 0.72; 95% CI: 0.41-1.25; p = 0.241) in TAVI.

Conclusion

This analysis suggests that amyloidosis may be associated with a higher risk of thromboembolism after TAVR. However, these data warrant further investigation.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Transcatheter Aortic Valve Replacement in Patients With Coexisiting Amyloidosis. Mortality, Stroke, and Readmission.

Reference: Mohammed Elzeneini, et al JACC Adv 2023;-:100255 Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....